Sanderling Ventures
-
Sotera Completes Series D
Private Equity Hub &bull Dec 15, 2011
Medical device company Sotera Wireless has closed a $12.2 million Series D financing led by Singapore-based global fund, EDBI. The round also included new investor Cerner Capital and existing investors Sanderling Ventures, Qualcomm Ventures, Intel Capital and West Health Investment… Full Story »
-
Naviscan Bolsters Board
Socal Tech &bull Jul 14, 2011
San Diego-based Naviscan, the developer of 3D medical imaging technology, said today that it has added Andre Cheng, M.D., Ph.D., to its board of directors. Cheng has previously served as VP of Medical Affairs and Reimbursement at Acclarent, in addition… Full Story »
-
Investor Profile: Sanderling Ventures
Funding Post &bull Jun 25, 2011
Robert McNeil, Ph.D., Managing Director, Sanderling Ventures Robert McNeil has over twenty-seven years experience as an active investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979 and has served since then as a Managing Director of Sanderling's six investment partnerships. Dr. McNeil was the seed investor for Western Technology Ventures, Advanced Cardiovascular Systems (acquired by Guidant Corp.) and Ventitrex… Full Story »
-
Inception 1 Raises $5M, VCs Pessimistic About U.S. Biotech Funding, EU Approves Amylin's Once-a-Week Diabetes Drug, & More San Diego Life Sciences News
X-Conomy &bull Jun 23, 2011
A global survey of venture capitalists released this week reveals substantial pessimism among VCs about venture investment levels in U.S. life sciences startups over the next five years. The annual survey by The National Venture Capital Association and Deloitte shows… Full Story »
-
Optimer Raises $77.6M, Former Sequenom Patent Agent Pleads Guilty, IPO Lineup Includes San Diego's Ambit and IASO Pharma, & More San Diego Life Sciences News
X-Conomy &bull Feb 17, 2011
With San Diego's Optimer and Conatus Pharmaceuticals successfully raising capital, and Sanderling Ventures reportedly planning to raise a new fund, it would be easy to think that the capital markets are opening a little for the life sciences sector. You… Full Story »
